Abaxis (ABAX) Declares $0.12 Quarterly Dividend; 0.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Abaxis Reports Financial Performance for the First Quarter of Fiscal 2017 and Declares a Quarterly Cash Dividend
July 21, 2016 4:01 PM EDTUNION CITY, Calif., July 21, 2016 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the first fiscal quarter ended June 30, 2016.
First quarter overview:
Record revenues of $57.7 million, up 9% over last year's comparable quarter. Diluted net income per share of $0.30, down 3% from last year's comparable quarter, resulting from an increase of 2 percentage points in operating expenses as a percentage of revenues, due to initiatives to increase investments in research and... MoreAbaxis Reports Financial Performance for the First Quarter of Fiscal 2017 and Declares a Quarterly Cash Dividend
July 21, 2016 4:01 PM EDTUNION CITY, Calif., July 21, 2016 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the first fiscal quarter ended June 30, 2016.
First quarter overview:
Record revenues of $57.7 million, up 9% over last year's comparable quarter. Diluted net income per share of $0.30, down 3% from last year's comparable quarter, resulting from an increase of 2 percentage points in operating expenses as a percentage of revenues, due to initiatives to increase investments in research and... More